Skip to content
DraconiticResearch
Search Sources API
190,869 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BYAlzheimer's & dementia : the journal of the Alzheimer's Association

The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders.

  • Yanaika S Hok-A-Hin1
  • Lisa Vermunt1
  • Natascha de Jong1
  • Marta Del Campo Milan2,3
  • Everard Vijverberg4
  • Afina W Lemstra4
  • Yolande Pijnenburg4
  • Argonde C van Harten4
  • Charlotte E Teunissen1
4 affiliations
  1. 1Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, North Holland, The Netherlands.
  2. 2Barcelonaßeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Catalonia, Spain.
  3. 3Hospital del Mar Research Institute, Barcelona, Catalonia, Spain.
  4. 4Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam UMC, Amsterdam, North Holland, The Netherlands.
Read full textPDFDOICite

Abstract

Introduction

Novel tools for absolute quantification of established and emerging fluid neuro-biomarkers are required to advance diagnostic studies and improve biological insights.Methods

We conducted an extensive analytical and clinical validation of the Olink™ Target 48 Neurodegeneration panel (T48 Neuropanel) in 352 paired cerebrospinal fluid (CSF) and plasma samples from cognitively unimpaired controls (CU), Alzheimer's dementia (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), n = 44 per group. Comparisons with benchmark assays were performed.Results

Good detectability (CSF: 31 out of 42 assays; plasma: 38 out of 42 assays) and technical performance was observed. Benchmark assays showed good correlations, supporting transformation formula's. Next to emerging biomarkers (MMP10, ITGB2), discriminative performance was excellent in AD: CSF pTau217: area under the curve (AUC) = 1; FTD: plasma neurofilament light chain (NfL): AUC = 0.952; and DLB: CSF dopa decarboxylase (DDC): AUC = 0.901.Discussion

This analytical and clinical validation of the T48 Neuropanel highlights initial cutoffs and emerging biomarkers to aid clinical studies for the diagnosis, prognosis, and monitoring of neurodegenerative diseases.

Related

  1. Harnessing Artificial Intelligence and ChatGPT in Early Detection of Neurodegenerative Disorders: A Transformative Opportunity for Neurology
    Roberto Tedeschi
    Acta Neurologica TaiwanicaPeer-reviewedCC BY-NC-SAFull text2 citedEpidemiology & public healthDOAJ
  2. Glymphatic Dysfunction Across Neurological Disorders: Links to Neurodegeneration, Inflammaging, Gut–Brain Signaling, and Physiological Modulators
    Konstantinos I. Voumvourakis, Nikolaos S. Thomaidis, Eleni Sideri +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Targeting Sirtuins in Neurodegenerative and Psychiatric Disorders: From Molecular Mechanisms to Pharmacological Modulation
    Andrei Florin Păduraru, Raluca-Sînziana Zaharia, Iuliana Roată +5
    Neurology internationalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. The Functional Connectivity of Hallucinations in Psychiatric Disorders and Neurodegenerative Disorders: A Systematic Review
    Yifan Ren, Huyen N. Pham, Xiong Xiong +5
    PsyArXivPreprintCC BY 4.0Full textNeurosciencePsychiatry & mental healthOSF
  5. Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders
    Zinan Zhou, Lovelace J. Luquette, Guanlan Dong +18
    CellPeer-reviewedCC BYFull text16 citedNeurologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{hokahin2026target48,
  title = {{The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders.}},
  author = {Yanaika S Hok-A-Hin and Lisa Vermunt and Natascha de Jong and Marta Del Campo Milan and Everard Vijverberg and Afina W Lemstra and Yolande Pijnenburg and Argonde C van Harten and Charlotte E Teunissen},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year = {2026},
  month = oct,
  doi = {10.1002/alz.71866},
  url = {https://europepmc.org/article/MED/42949229},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - The Target48 Neurodegeneration panel: A novel tool for profiling protein signatures in neurodegenerative disorders.
AU  - Yanaika S Hok-A-Hin
AU  - Lisa Vermunt
AU  - Natascha de Jong
AU  - Marta Del Campo Milan
AU  - Everard Vijverberg
AU  - Afina W Lemstra
AU  - Yolande Pijnenburg
AU  - Argonde C van Harten
AU  - Charlotte E Teunissen
PY  - 2026
DA  - 2026/10/01
JO  - Alzheimer's & dementia : the journal of the Alzheimer's Association
DO  - 10.1002/alz.71866
UR  - https://europepmc.org/article/MED/42949229
AB  - Introduction  Novel tools for absolute quantification of established and emerging fluid neuro-biomarkers are required to advance diagnostic studies and improve biological insights.Methods  We conducted an extensive analytical and clinical validation of the Olink™ Target 48 Neurodegeneration panel (T48 Neuropanel) in 352 paired cerebrospinal fluid (CSF) and plasma samples from cognitively unimpaired controls (CU), Alzheimer's dementia (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), n = 44 per group. Comparisons with benchmark assays were performed.Results  Good detectability (CSF: 31 out of 42 assays; plasma: 38 out of 42 assays) and technical performance was observed. Benchmark assays showed good correlations, supporting transformation formula's. Next to emerging biomarkers (MMP10, ITGB2), discriminative performance was excellent in AD: CSF pTau217: area under the curve (AUC) = 1; FTD: plasma neurofilament light chain (NfL): AUC = 0.952; and DLB: CSF dopa decarboxylase (DDC): AUC = 0.901.Discussion  This analytical and clinical validation of the T48 Neuropanel highlights initial cutoffs and emerging biomarkers to aid clinical studies for the diagnosis, prognosis, and monitoring of neurodegenerative diseases.
SN  - 1552-5260
SN  - 1552-5279
ER  -